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Abstract
Neoadjuvant therapy, also known as primary, induction, or
preoperative therapy, is defined as the first systemic treatment a
patient receives after cancer is diagnosed and indicates that
subsequent therapies are intended. It was first used in the early
1970s for the treatment of inoperable locally advanced or
inflammatory breast cancer. Based on a large body of clinical
evidence and on the fact that primary breast cancer is today
considered a systemic disease with a locoregional component,
primary systemic therapy is now increasingly considered for
women with operable disease for reducing mortality with lower
toxicity, improving surgical options, and acquiring early information
on response and biology of the disease.
According to the recommendations of an international expert
panel on the use of primary systemic therapy (PST) of
operable breast cancer, a PST with cytotoxic agents is
preferred when breast-conserving surgery (BCS) is not
possible or is likely to be suboptimal in terms of the cosmetic
results or in patients whose tumors express markers of good
response to chemotherapy such as low or absent hormone
receptor status, high grade, and non-lobular invasive
histology [1]. At least six cycles should be administered over
the course of 4 to 6 months before surgery [1].
Preoperative endocrine therapy may be effective but its use
as PST alone is appropriate mainly for frail postmenopausal
patients or elderly patients in whom surgery would carry
increased risk due to the advanced age or comorbidities of
the patient [2]. Until now, there have been no data that
accurately define which patients with estrogen receptor (ER)-
positive disease benefits from neoadjuvant chemotherapy
and for whom endocrine therapy would be sufficient. Current
research efforts aim to identify molecular markers at surgery
which predict long-term efficacy of neoadjuvant/adjuvant
endocrine treatment.
Induction of a pathologic complete response (pCR) should
be one of the primary goals of neoadjuvant therapy because
patients with no evidence of tumor cells in the breast or in the
lymph nodes after treatment may have a longer disease-free
survival (DFS) and overall survival (OS) [3]. Before any PST is
started, a core biopsy should be performed to confirm the
diagnosis of invasive cancer and to obtain predictive markers
such as histological subtype, tumor grading according to
Elston and Ellis, ER and progesterone receptor status, and
HER2 status [1].
Experiences from clinical studies
A number of clinical trials have evaluated the role of
neoadjuvant chemotherapy for breast cancer. One of the
pioneering studies for the PST concept was the National
Surgical Adjuvant Breast and Bowel Project (NSABP) B-18,
which randomly assigned 1,523 women with operable breast
cancer to receive four cycles of adriamycin and cyclophos-
phamide (AC) either before or after definitive surgery. In the
group treated with preoperative chemotherapy, a rate of pCR,
defined as the absence of residual malignant cells at the site
of the primary tumor irrespective of the status of axillary
nodes, of 13% was observed, with a significantly higher rate
of breast conservation compared with surgery first (67%
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versus 60%; P = 0.002), especially in patients with tumors
larger than 5 cm in diameter [4].
At a median follow-up of 9 years, comparison between the
groups treated with neoadjuvant and with adjuvant therapies
revealed no statistically significant overall differences in either
DFS or OS [5]. However, a statistically significant correlation
was shown between primary tumor response and outcome:
individuals achieving a pCR experienced significantly improved
outcomes compared with non-pCR subjects, including 9-year
DFS (75% versus 58%) and OS (85% versus 73%), and a
50% decrease in the risk of death compared with all other
pathologic markers (relative risk 0.50, 95% confidence interval
[CI] 0.32 to 0.78).
In a similar study design, the European Organization for
Research and Treatment of Cancer (EORTC) randomly
assigned 698 women to anthracycline-based chemotherapy
before or after surgery [6]. As shown in the NSABP B-18
trial, there was no significant difference in terms of OS
(hazards ratio [HR] 1.16; P = 0.38), progression-free survival
(HR 1.15; P = 0.27), or time to locoregional recurrence (HR
1.13;  P = 0.61) at a median follow-up of 56 months. Fifty-
seven patients (23%) were downstaged by the preoperative
chemotherapy, whereas only 14 women (18%) underwent
mastectomy and not the planned breast-conserving therapy.
To examine the role of neoadjuvant taxane, the NSABP
randomly assigned 2,411 women in study B-27 to neo-
adjuvant AC alone, to neoadjuvant AC followed by docetaxel
before surgery, or to neoadjuvant AC followed by adjuvant
docetaxel after surgery. Compared with preoperative AC
alone, preoperative AC followed by docetaxel increased the
clinical complete response (cCR) rate (40.1% versus 63.6%;
P <0.001), the overall clinical response rate (85.5% versus
90.7%;  P <0.001), the pCR rate (13.7% versus 26.1%;
P <0.001), and the proportion of patients with negative
nodes (50.8% versus 58.2%; P <0.001) [7]. Pathologic
primary breast tumor response was a significant predictor of
pathologic nodal status (P <0.001). At a median follow-up of
6.5 years, women achieving pCR demonstrated significantly
improved survival compared with those without pCR (HR
0.33, 95% CI 0.23 to 0.47; P <0.0001) [8].
In the European Cooperative Trial in Operable breast cancer
(ECTO), women with operable breast cancer (primary tumor
greater than 2 cm) were randomly assigned to adjuvant
doxorubicin (75 mg/m2 every 21 days) for four cycles followed
by CMF (cyclophosphamide, methotrexate, and 5-fluorouracil)
or to adjuvant doxorubicin (60 mg/m2) and paclitaxel
(200 mg/m2 over the course of 3 hours every 21 days) for
four cycles followed by CMF (AT-CMF) or to AT-CMF as
PST, yielding a cCR in 52% of patients (27% after AT and
25% more after CMF) [9]. pCR was documented in 23% of
specimens and was associated with negative axillary nodes in
87%. Conservative surgery was more frequent after PST
(71% versus 35% before adjuvant therapy; P <0.00001)
regardless of tumor size at diagnosis. The frequency of
pathologically negative nodes was also significantly higher in
the PST group (61% versus 38%).
During the same meeting, the results of the German Gyneco-
logical Oncology Working Group (Arbeitsgemeinschaft
Gynäkologische Onkologie, or AGO) study were also presen-
ted, demonstrating the feasibility of a dose-dense biweekly
protocol [10]. This trial was designed to compare the fre-
quency of BCS, the response rates, and the safety between
two epirubicin- and paclitaxel-containing regimens given either
as dose-dense sequential intensified chemotherapy (arm A) or
in a standard dose (arm B), both as preoperative therapy for
primary breast cancer. Patients with large primary tumors
(>3 cm) or inflammatory disease were randomly assigned to
receive either three cycles of epirubicin 150 mg/m2 followed
by three cycles of paclitaxel 250 mg/m2 every 2 weeks with
granulocyte colony-stimulating factor support or four cycles of
combination epirubicin 90 mg/m2 and paclitaxel 175 mg/m2
every 3 weeks as preoperative therapy. A total of 631 patients
were enrolled. Preliminary data from 475 patients
demonstrated a significantly higher frequency of BCS (66%
versus 55%; P = 0.016), pCR (18% versus 10%; P = 0.03),
and negative axillary lymph nodes at surgery (51% versus
42%; P = 0.098) with the every-2-week regimen.
The phase III GeparDuo (the second German Preoperative
Adriamycin and Docetaxel (GerparDo) trial) (n = 913) of the
German Adjuvant Breast Cancer Group (GABG) compared
the pathologic locoregional complete response rate achieved
with preoperative administration of the 8-week dose-dense
combination regimen ADOC (doxorubicin 50 mg/m2 plus
docetaxel 75 mg/m2 every 14 days for four cycles with filgra-
stim support), as studied in the predecessor study GeparDo,
with that of a 24-week sequential schedule of AC followed by
docetaxel (AC-DOC) (doxorubicin 60 mg/m2 plus cyclophos-
phamide 600 mg/m2 every 21 days followed by docetaxel
100 mg/m2 every 21 days for four cycles each), similar to one
of the treatment arms in the NSABP B-27 trial [11].
A pCR was achieved in 94 patients (10.6%), but the
likelihood was significantly greater with AC-DOC (14.3%;
n = 63) than with the ADOC regime (7.0%; n = 31) (odds
ratio 2.22, 90% CI 1.52 to 3.24; P <0.001). Independent
predictors of achieving a pCR included the use of sequential
therapy, high tumor grade, and negative hormone receptor
status. The response rates detected by palpation and by
imaging were significantly higher with AC-DOC (85.0% and
78.6%, respectively) than with ADOC (75.2% and 68.6%,
respectively; both P values <0.001). The rates of BCS were
63.4% for AC-DOC and 58.1% for ADOC (P = 0.05).
Evaluation of early response
As shown in the studies, women with an early or mid-course
response to neoadjuvant chemotherapy have chemosensitivetumors and a high probability for a pCR at surgery. Therefore,
assessing early tumor response to chemotherapy is crucial to
avoid unnecessary toxicity without potential benefit from the
treatment. Neoadjuvant chemotherapy response is currently
achieved by monitoring changes in tumor size using clinical
examination based on palpable change in tumor size backed
up by mammography and/or ultrasound.
Relevant changes (for example, partial remissions, defined as
a reduction in the product of the two largest perpendicular
diameters of the primary tumor size by 50% or more) in tumor
size can be observed at as early as 4 to 6 weeks (that is, two
cycles) of chemotherapy. Early detection of response might
therefore be used as follows [2]:
￿ as a predictor of pathologic response
￿ as a predictor of long-term outcome
￿ as a decision aid to switch therapy
￿ to identify patients who might or might not benefit from a
switch in therapy.
One approach to use this early information on response in the
clinical setting to tailor further treatment strategies for
individual patient therapy has been evaluated in the
GeparTrio trial, the first prospective randomized study to
address patients with tumors that do or do not show an early
response [12]. Of 2,090 patients enrolled in the GeparTrio
study, 622 (29.8%) who did not respond to two initial cycles
of TAC (docetaxel at 75 mg/m2, doxorubicin at 50 mg/m2,
and cyclophosphamide at 500 mg/m2) with a decrease in
tumor size by at least 50% were randomly assigned to switch
to a  better tolerated non-cross-resistant regimen consisting
of four additional cycles of TAC (n = 321) or to four cycles of
vinorelbine at 25 mg/m2 and capecitabine at 2,000 mg/m2
(NX) (n = 301).
Sonographic response rates were 50.5% for the TAC arm
and 51.2% for the NX arm. The difference of 0.7% (95% CI
–7.1% to 8.5%) demonstrated non-inferiority of NX
(P = 0.008). Similar numbers of patients in the two arms
received BCS (184 [57.3%] in the TAC arm versus 180
[59.8%] in the NX arm) and had a pCR (5.3% versus 6.0%).
Fewer patients in the NX arm than in the TAC group had
hematological toxic effects, mucositis, infections, and nail
changes, but more had hand-foot syndrome and sensory
neuropathy. In conclusion, pCRs to both regimens were
marginal. Among patients who did not respond to the initial
neoadjuvant TAC treatment, similar efficacy but better
tolerability was observed by switching to NX than continuing
with TAC.
The GeparTrio study also examined the benefit of an
intensified neoadjuvant chemotherapy regime consisting of
an additional four (n = 704) or six (n = 686) TAC cycles for
those women who responded to two initial cycles of TAC
(n = 1,390) [13]. Patients receiving a total of eight TAC
cycles had statistically significantly higher sonographic
response rates, but not pCR rates, than those receiving six
TAC cycles. However, eight TAC cycles showed more side
effects. Therefore, eight cycles of TAC cannot be
recommended for the whole group of patients responding to
two initial cycles of TAC.
Predictors of response
Efforts have been made to identify more accurately the
likelihood of pCR under neoadjuvant chemotherapy. The
most important predictive marker concerning response to a
preoperative taxane-anthracycline-based regimen is negative
hormone receptor status. However, despite a pathologic
complete remission rate exceeding 40%, survival of patients
with this phenotype was reported in several studies to be
shorter than for those with receptor-positive tumors [1].
Some studies identified a lower response rate for operable
invasive lobular carcinomas. So far, trials with various
biological markers like HER2 and topoisomerase IIa have
revealed heterogeneous data concerning the prediction of
response to specific therapies. Currently, a set of biological
markers, rather than a single one, seem to be important to
differentiate between a high or low chance for a pCR.
New primary systemic therapy concepts
Patients with no pCR have a significant risk of recurrent
disease, and currently no further standard therapy exists.
Therefore, alternative regimens are urgently needed to
improve therapeutic outcomes for this high-risk population.
Ongoing or not-yet-published neoadjuvant trials integrate
modern concepts of treatment like tumor targeting with new
biological agents or bisphosphonates.
The phase III GeparQuattro study conducted by the AGO
and German Breast Group (GBG) study groups is the largest
neoadjuvant clinical trial in women with HER2-positive breast
cancer. One thousand five hundred and ten women received
four cycles of EC (epirubicin 90 mg/m2 and cyclophosphamide
600 mg/m2) and were randomly assigned to either four
cycles of docetaxel (100 mg/m2) (arm A) or four cycles of
docetaxel (75 mg/m2) plus capecitabine (1,800 mg/m2) (arm
B) or four cycles of docetaxel (75 mg/m2) followed by four
cycles of capecitabine (1,800 mg/m2) (arm C) (Figure 1).
Women with HER2-positive tumors (n = 456) received trastu-
zumab 6 (8) mg/kg of body weight every 3 weeks conco-
mitantly with all neoadjuvant chemotherapy before surgery
and for up to 1 year after surgery. To minimize the cardiac
risk, patients with any previous heart problems and/or an
ejection fraction below 55% were excluded. As the analysis
of efficacy has shown, the pCR rate (primary endpoint) in
women with HER2-positive tumors was significantly
increased by the addition of trastuzumab (45.5% versus
19.5%) (Figure 2). The addition of trastuzumab to the
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without clinically relevant cardiotoxicity [14] (Figure 3). The
addition of capecitabine, neither concomitantly nor in
sequence, did not improve the pCR rate.
The multicenter phase II TECHNO (Taxol-Epirubicin-Cyclo-
phosphamide-Herceptin Neoadjuvant) study of the AGO
evaluates preoperative 4 × EC 90/600 mg/m2 every 3 weeks
followed by 4 × paclitaxel 175 mg/m2 every 3 weeks with a
trastuzumab loading dose of 8 mg/kg followed by 6 mg/kg
every 3 weeks, followed by surgery and postoperative
trastuzumab 6 mg/kg every 3 weeks for 9 months in 230
patients with HER2-positive breast cancer (immunohisto-
chemistry 3+ or fluorescence in situ hybridization [FISH]-
positive confirmed by central pathology) [15]. Radiotherapy
and endocrine therapy were applied according to standard
recommendations. In 119 analyzed patients, 37% achieved a
histopathologic complete response and 17% had only
residual ductal carcinoma in situ in the breast. Seventy-three
percent of women showed histologically negative axillary
nodes at surgery. Updated data were scheduled to be
available at the end of last year.
The currently recruiting, randomized, open-label multicenter
phase III Neo-ALTTO (Neoadjuvant Lapatinib and/or Trastu-
zumab Treatment Optimisation) study is comparing the
efficacy of neoadjuvant lapatinib (a novel orally active small-
molecule and dual-tyrosine kinase inhibitor of both epidermal
growth factor receptor and HER2) plus paclitaxel, versus
trastuzumab plus paclitaxel, versus concomitant lapatinib and
trastuzumab plus paclitaxel given as neoadjuvant treatment in
HER2-overexpressing and/or amplified primary breast cancer
(Figure 4). Patients will be randomly assigned to receive
lapatinib 1,500 mg daily, trastuzumab 4 mg/kg intravenous
(iv) load followed by 2 mg/kg iv weekly, or the lapatinib
1,000 mg daily with trastuzumab 4 mg/kg iv load followed by
2 mg/kg iv weekly for a total of 6 weeks. After this biological
window, patients will continue on the same targeted therapy
plus weekly paclitaxel 80 mg/m2 for a further 12 weeks, up to
definitive surgery. After surgery, patients will receive three
courses of adjuvant chemotherapy with FEC followed by the
same targeted therapy as in the neoadjuvant setting for a
further 34 weeks. The planned total duration of the anti-HER2
therapy will be 1 year. The primary objective of this study is to
evaluate and compare the rate of pCR at the time of surgery
(18 weeks) in patients randomly assigned to receive
neoadjuvant lapatinib or trastuzumab or their combination
plus paclitaxel. The estimated enrollment will be 450 patients.
The study started in November 2007 and will be completed
in September 2009.
The PREPARE (Preoperative Epirubicin Paclitaxel Aranesp)
phase III study was initiated in 2002 and was developed,
conducted, and analyzed by the AGO and GBG. It was
designed to evaluate the relapse-free survival time and OS of
a sequential dose-dense and dose-intensified regimen of
epirubicin, paclitaxel, and CMF compared with preoperative
sequential administration of epirubicin and cyclophos-
phamide followed by paclitaxel sequential interval-shortened
and dose-intensified preoperative use of epirubicin, paclitaxel,
and CMF with preoperative sequential administration of
epirubicin and cyclophosphamide followed by paclitaxel in
Breast Cancer Research    Vol 11 No 2 Untch and von Minckwitz
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Figure 1
Study design of the GeparQuattro study. EC, epirubicin and cyclophosphamide; ER, estrogen receptor; OP, operation (surgery); PR, partial
response; R, random assignment; T, trastuzumab; X, capecitabine. Reprinted with permission [17].733 women with primary breast cancer. Pegfilgrastim was
used as a secondary preventive after febrile neutropenia in
the standard arm of the study or, in exceptional cases, after
severe febrile neutropenia necessitating the postponement of
treatment by more than 1 week. In addition, the influence of
darbepoetin alfa on response rate and quality of life was
investigated in both treatment arms. An interim analysis
showed that the pCR rate was significantly higher in the
dose-intensified arm compared with the standard arm (18.7%
versus 13.2%; P = 0.0425). The use of darbepoetin alfa to
support neoadjuvant chemotherapy kept hemoglobin levels
stable and had no significant impact on tumor response to
chemotherapy at the time of surgery [16]. Long-term follow-
up data showed no differences with regard to the comparison
of the two chemotherapy regimen. However, there were more
relapses and deaths in the group of patients treated with
darbepoetin alpha.
The current study of the GBG and AGO groups, Gepar-
Quinto, is addressing three questions with randomizations for
separate subgroups: (1) In patients with HER2-negative
tumors, we investigate the role of bevacizumab given con-
comitantly to epirubicin/cyclophosphamide (EC) followed by
docetaxel (D) chemotherapy. (2) In patients with HER2-
negative tumors not responding to EC with or without beva-
cizumab, we investigate the role of Everolimus (RAD 001) in
combination with paclitaxel. (3) In patients with HER2-
positive tumors we compare lapatinib against trastuzumab
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Figure 2
GeparQuattro study: pathologic complete response (pCR) rates in women with HER2-positive or -negative breast cancer.
Figure 3
GeparQuattro study: cardiac events in women with HER2-positive and -negative breast cancer. CHF, congestive heart failure; CTC, crackle
transmission coefficient; LVEF, left ventricular ejection fraction.given concomitantly with EC-D. As of March 2009, the trials
have recruited 600 out of 2400 patients.
Conclusions
Neoadjuvant chemotherapy for early breast cancer is a major
development with important implications for the management
of this disease. Originally used only in women with locally
advanced inoperable breast cancer, PST can now be offered
as a very good option for primary operable disease in patients
who are candidates for adjuvant systemic chemotherapy,
irrespective of the size of the tumor [1].
The available data suggest a significant and important
correlation between pCR after neoadjuvant therapy and DFS
as well as OS. Moreover, PST increases the rate of BCSs
and is associated with a lower rate of positive axillary lymph
nodes at the time of surgery [1]. The preoperative addition of
a taxane to preoperative AC results in a significant increase in
the rate of cCR, pCR, and negative axillary nodes in patients
with operable breast cancer.
At least six cycles of an anthracycline- and taxane-containing
regimen should be planned and given preoperatively over the
course of 4 to 6 months [1]. Trastuzumab is recommended
for patients with HER2-positive tumors. The concurrent use
of the anti-HER2 antibody with an anthracycline-containing
regimen should be given only in clinical trials. Individualization
of neoadjuvant therapy for breast cancer according to mid-
course response or to molecular tumor characteristics will be
one of the most important goals in the coming years.
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